InvestorsHub Logo
Followers 144
Posts 27636
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Tuesday, 01/02/2024 5:01:09 AM

Tuesday, January 02, 2024 5:01:09 AM

Post# of 2839

Bioline, which developed a drug to mobilize stem cells for bone marrow transplants,
received approval in September and is launching these days.
The product has been incorporated into the treatment protocol of the NCCN network
of cancer centers, which is a good start in the American market.
Bioline itself is responsible for marketing.
As of the end of the third quarter, the company has enough cash until the year 2025.


https://www.globes.co.il/news/article.aspx?did=1001466522

The article is in Hebrew, this paragraph was Google translated.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLRX News